Los Angeles Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
Other funds holding RXRX
AIM
VPM
VCM
MCMU
Los Angeles Capital Management's RXRX Position: Q1 2026 in Review
Los Angeles Capital Management increased its Recursion Pharmaceuticals (RXRX) stake by 671% in Q1 2026, buying an estimated $1.13M and bringing the position to 335,624 shares worth $1.03M. The position accounts for ﹤0.01% of the portfolio, ranked #670.
Los Angeles Capital Management first reported a position in RXRX in Q2 2024 and has held it in 5 quarters since. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.
- Los Angeles Capital Management held 335,624 shares of Recursion Pharmaceuticals worth $1.03M as of Q1 2026.
- Los Angeles Capital Management bought 292,113 Recursion Pharmaceuticals shares in Q1 2026, an estimated $1.13M.
- Recursion Pharmaceuticals made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #670 holding.
- Los Angeles Capital Management first reported a position in Recursion Pharmaceuticals in Q2 2024 and has held it in 5 quarters since.
- 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.
Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.